[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"time-in-range\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:time-in-range":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,72,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100512089","real-time-continuous-glucose-monitoring-system-in-t2dm-with-pregnacy-100512089",false,"NCT05947916","Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy","Effect of Real Time Continuous Glucose Monitoring System on Management of Women With Type 2 Diabetes Mellitus During Pregnancy in a Multidisciplinary Comprehensive System","Inclusion Criteria:\n\n* A clear history of type 2 diabetes, or a history of type 2 diabetes diagnosed in early pregnancy\n* Singleton gestation at 4-26 weeks, with substandard glycemic control (i.e., fasting glucose \\> 5.3 mmol\u002FL, and or 1 hour postprandial glucose \\> 7.8 mmol\u002FL, and or 2 hours postprandial glucose \\> 6.7 mmol\u002FL) after lifestyle intervention ± basal insulin therapy, as assessed by the endocrinology department. Patients who need insulin regimen with basal plus meal or insulin pump regimen.\n* Patients are willing and committed to establish and follow up in the obstetrics and gynecology departments of Peking University Third Hospital, Haidian District Hospital and Yanqing District Hospital during pregnancy, and are willing to provide information on obstetric examination and perinatal medical records if they are transferred to the hospital for special reasons for follow-up or delivery.\n* Voluntarily participate in the study, examine and follow up according to this project and sign informed consent.\n* Able to pass the screening period Adherence evaluation\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes, specific type of diabetes or gestational diabetes\n* Pregnancy with severe comorbidities or diabetic complications for which obstetrics does not recommend continuation of pregnancy, including but not limited to the following: proliferative retinopathy, chronic kidney disease (eGFR less than 60 mL\u002Fmin\u002F1.73± massive proteinuria), known coronary and cerebrovascular disease, autoimmune system disease and receiving exogenous glucocorticoids or immunosuppressive therapy.\n* Patients who have been hospitalized for psychiatric treatment within 6 months prior to enrollment or are still on psychiatric medications.\n* Patients who have received other interventional studies.","FEMALE","18 Years","40 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","The prevalence of type 2 diabetes mellitus (T2DM) in women of childbearing age is increasing rapidly, and low glucose compliance leads to an increased risk of adverse pregnancy outcomes for mothers and infants during pregnancy in women with T2DM. Real-time continuous glucose monitoring (CGM) is an important tool for glucose monitoring and patient education, as it can continuously record blood glucose throughout the day and provide real-time feedback on high and low blood glucose levels. This is a multicenter, open-label, randomized controlled clinical study to investigate the efficacy, safety, and maternal and infant pregnancy outcomes of using real-time CGM monitoring compared with conventional self-monitoring of blood glucose (SMBG) on the basis of multidisciplinary management in pregnant women with T2DM. One hundred and twenty pregnant women with T2DM in early pregnancy who were enrolled in intensive insulin therapy were randomly divided into the real-time CGM group and the conventional SMBG group. The real-time CGM intervention group wore real-time CGM for more than 50% of the pregnancy in addition to regular SMBG; the control group only performed regular SMBG. Both groups wore Medtronic iPro 2 for 3 days in early, mid and late pregnancy, and the time in the target range of blood glucose (TIR) was recorded in a blinded manner. Primary outcome: differences in TIR between the two groups of pregnant women in early, mid, and late pregnancy. Secondary outcomes included differences in glycated hemoglobin, hypoglycemia, insulin dose before delivery, pregnancy weight gain, and maternal and infant pregnancy outcomes.",[27,28,29,30,31],"Type2diabetes","Pregnancy Related","Continuous Glucose Monitoring","Time in Range","Pregnancy Outcome","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2024-01-30",{"date":40,"type":21},"2026-12-31",{"name":42,"class":43},"Peking University Third Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":44},"100644010","efficacy-of-the-use-of-real-time-continuous-glucose-monitoring-on-glycemic-control-in-patients-with-type-2-diabetes-and-stage-3-and-4-chronic-kidney-disease-100644010","NCT07668219","Efficacy of the Use of Real-time Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes and Stage 3 and 4 Chronic Kidney Disease.","4.2.1 Inclusion Criteria\n\n* Age over 18 years\n* Chronic kidney disease defined as a glomerular filtration rate (GFR) of less than 60 ml\u002Fmin\u002F1.73 m², in at least two measurements within the six months prior to inclusion.\n* Treatment with basal insulin, basal-bolus regimen, or co-formulation with or without oral antidiabetic agents, with or without a GLP-1 analogue, with stable treatment for the last 3 months.\n\n4.2.2 Exclusion Criteria\n\n* Type 1 diabetes.\n* Severe cognitive impairment or dysfunction that prevents device management.\n* Chronic kidney disease on renal replacement therapy (peritoneal dialysis or hemodialysis).\n* Patients with a history of kidney transplantation.","ALL",{"count":53,"type":21},30,[24],"* Rationale: Glucose control in patients with kidney disease is challenging, as traditional metrics can be unreliable and there is a high risk of hypoglycemia (low blood sugar). Although RT-CGM has shown benefits in other groups, its efficacy in patients with advanced kidney damage needs to be validated to improve their quality of life and prevent disease progression.\n* Main objective: To determine whether the use of RT-CGM is more effective than usual care (capillary blood glucose monitoring with a glucometer) in maintaining patients within an optimal glucose range (70-180 mg\u002FdL) over a three-month period.\n* Study population: We plan to include 30 patients over 18 years of age with type 2 diabetes and chronic kidney disease (with a glomerular filtration rate less than 60 ml\u002Fmin), who use insulin and are not on renal replacement therapy such as dialysis.\n* Methodology: The study is a randomized clinical trial consisting of two phases:\n\n  1. Selection period (15 days): Blinded monitoring is performed to obtain baseline data.\n  2. Treatment period (90 days): Patients are divided into two groups: the intervention group, which will use the CGM-RT with alarms configured for high and low levels, and the control group, which will continue with traditional fingerstick monitoring.\n* Metrics to be evaluated: In addition to time in range, researchers will analyze episodes of hypoglycemia and hyperglycemia, glycemic variability, glycated hemoglobin (HbA1c) levels, and device accuracy.\n* Ethical and logistical considerations: The study complies with international and national regulations, guaranteeing the confidentiality and autonomy of the participants. The project has a 24-month timeline and a detailed budget to cover medical personnel, monitoring sensors (Sinocare i3), and laboratory tests.",[57,58,59,30],"Type 2 Diabetes","Kidney Disease","CGM",[57,58,29,61],"Time in range","NOT_YET_RECRUITING","2026-06-19",{"date":65,"type":36},"2026-06-25",{"date":67,"type":21},"2026-11",{"date":69,"type":21},"2027-05-30",{"name":71,"class":43},"Hospital Universitario San Ignacio",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":51,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100644231","influence-of-the-use-of-specific-nutritional-formulas-on-time-in-range-in-patients-with-type-2-diabetes-100644231","NCT07666581","Influence of the Use of Specific Nutritional Formulas on Time in Range in Patients With Type 2 Diabetes","Influence of the Use of Specific Nutritional Formulas for Diabetes on Time in Range in Patients With Type 2 Diabetes Mellitus With Obesity by Freestyle Continuous Glucose Monitoring","Inclusion criteria:\n\n* Patients over 18 years of age.\n* Diagnosis of diabetes mellitus type 2.\n* HbA1c \\>7% to \\\u003C11%.\n* BMI \\>27 kg\u002Fmt2 \\\u003C35 kg\u002Fmt2\n* Current use of continuous glucose monitoring with adherence greater than 70%.\n* Access to technology to download data from CGM in a timely manner.\n* Ability to follow the study protocol and provide informed consent (Appendix 3).\n\nExclusion criteria:\n\n* Change in antidiabetic medication in the last 3 months.\n* Pregnancy or lactation or planning to become pregnant during the study period.\n* Acute decompensation of diabetes in the past 3 months.\n* Participation in another clinical trial.\n* Use of glucocorticoids or insulin in the past 3 months or planned use in the coming months.\n* Initiation of treatment with oral or injectable GLP-1 analogues 3 months prior to enrollment.\n* History of bariatric surgery or gastrointestinal pathology associated with malabsorption syndromes.",{"count":80,"type":21},198,[24],"Who can participate?\n\nIndividuals may be eligible to join this study if they meet the following criteria:\n\n* Are 18 years or older.\n* Have Type 2 diabetes with an A1c level higher than 7%.\n* Have a Body Mass Index (BMI) between 27 and 35 (considered overweight or Class 1 obesity).\n* Have used a continuous glucose monitor (CGM) successfully in the past.\n\nHow the study works:\n\nIf eligible individuals decide to join and sign the consent form, a computer will randomly assign them into one of two groups:\n\nThe Formula Group: Participants will replace their usual breakfast and one snack with a specific diabetes nutritional drink (Glucerna®).\n\nThe Standard Diet Group: Participants will follow a standard low-calorie meal plan without using the nutritional drink.\n\nBoth groups will aim for a specific daily calorie goal (1,200-1,500 for women; 1,500-1,800 for men) and will receive expert nutritional counseling.\n\nMonitoring and Follow-up\n\nOver the course of 3 months, close contact will be maintained to support participants:\n\nEvery 2 weeks: A nutrition expert will call participants to check on their diet and help with their glucose monitor.\n\nEvery month: Participants will meet with the study team in person to review glucose monitor data.\n\nTests: At the start and end of the study, weight, body composition, blood sugar (A1c), and cholesterol levels will be measured to see how the plans worked.",[57,84,30],"Obesity & Overweight",[57,86,87,30],"Obesity","Continuos Glucose Monitoring","2026-06-18",{"date":90,"type":36},"2026-06-24",{"date":92,"type":21},"2026-08",{"date":94,"type":21},"2028-12",{"name":71,"class":43},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":51,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":44},"100573104","evaluating-an-insulin-pump-for-time-in-range-tir-in-patients-with-type-1-diabetes-100573104","NCT06741943","Evaluating an Insulin Pump for Time in Range (TIR) in Patients with Type 1 Diabetes","A Prospective, Multicenter, Open-label Study Evaluating an Insulin Pump (model: AR-B200A) for Time in Range (TIR) in Patients with Type 1 Diabetes","Inclusion Criteria:\n\nSubjects must meet all of the following criteria to be enrolled:\n\n1. Age between 8 and 75 years old, regardless of gender;\n2. Subjects with T1DM (including adult occult autoimmune diabetes mellitus (LADA)) who have been judged by investigators to require insulin pump therapy;\n3. Subjects who are able to cooperate with insulin pump therapy and derive weekly data from insulin pump during study treatment;\n4. During the study period, the subject's total daily insulin should be ≥8 units;\n5. Subjects who are able to follow a diabetic diet;\n6. Those who can voluntarily sign informed consent.\n\nExclusion Criteria:\n\nSubjects are excluded if they meet any of the following criteria:\n\n1. Hyperglycemia with severe circulatory disorders and shock;\n2. Acute complications of diabetes (such as diabetic ketoacidosis, diabetic hyperosmolar non-ketotic coma);\n3. A history of 2 or more episodes of severe hypoglycemia leading to medical assistance, coma or seizure in the 6 months prior to screening;\n4. The presence of at least 4 hypoglycemic symptoms, occurrence or detection of hypoglycemic events within 1 month before screening;\n5. Patients with hyperthyroidism;\n6. Any serious systemic disease determined by the investigator or any other disease that the investigator believes may interfere with the results of this study, including but not limited to mental illness, immune system disease, malignancy, etc.;\n7. Patients who developed the following cardiac conditions in the 6 months prior to screening: a) decompensated cardiac insufficiency (New York College of Cardiology (NYHA) Class III or IV); b) unstable angina; c) History of myocardial infarction, coronary artery bypass grafting, or coronary stent implantation; d) Uncontrolled or severe arrhythmia;\n8. Patients with the following cerebrovascular diseases in the 6 months before screening: a) transient ischemic attack; b) stroke;\n9. Subjects with sickle cell anaemia, thalassaemia or hemoglobinopathy;\n10. Subjects who have received, or plan to receive, red blood cell transfusions or erythropoietin (EPO) therapy within the 3 months prior to screening;\n11. Used immunosuppressants, cytotoxic drugs, systemic steroid drugs (excluding topical or inhaled preparations) for more than 7 days in the 3 months prior to screening or planned to be used during the study period;\n12. Screening subjects who have used hormone therapy for 3 or more consecutive days in the preceding 3 months, are currently using, or plan to use systemic hormone therapy during the study period;\n13. Present with known proliferative retinal lesions or other history of visual impairment;\n14. History of hearing loss;\n15. Impaired liver and kidney function (total bilirubin \\> 1.5 times the upper limit of normal, alanine aminotransferase (ALT) \\> 2.5 times the upper limit of normal; Glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73m2);\n16. Subjects with erythrocyte specific volume lower than the lower limit of normal laboratory values;\n17. Patients with abnormal coagulation function (activated partial thromboplastin time (APTT) or prothrombin time (PT) test results \\>1.5 times the upper limit of normal value);\n18. Participants who plan to use drugs containing acetaminophen, vitamin C, etc. that affect blood glucose measurement during the study period;\n19. Major surgery is planned during the study period and will directly affect subjects treated with insulin pumps;\n20. Subjects who do not have self-glucose monitoring conditions or do not accept home self-glucose monitoring;\n21. People who are allergic to glucose sensors, subcutaneous infusion sets, and medical tape;\n22. There are adverse skin conditions (such as diffuse subcutaneous nodules, psoriasis, rash, staphylococcal infection, psoriasis, scars, stretch marks, etc.) at the site where the glucose sensor and insulin pump subcutaneous infusion device are planned to be placed;\n23. Subjects who are unwilling to bury the infusion tube subcutaneously or wear the pump for a long time, and psychologically do not accept insulin pump treatment;\n24. Subjects and their families lacked relevant knowledge and were unable to correctly master the user after receiving training (excluding subjects who were hospitalized or admitted to the hospital during the study period for insulin pump operation by a doctor\u002Fnurse);\n25. Subjects with poor compliance, unable to cooperate with intensive treatment or irregular exercise;\n26. Young or elderly subjects who are unable to take care of themselves and have no guardian;\n27. Subjects who are not able to use effective contraception during pregnancy, lactation or during the study;\n28. Participated in other clinical trials within 3 months prior to screening;\n29. Other conditions deemed unsuitable for inclusion by the researcher.","8 Years","75 Years",{"count":106,"type":21},60,[24],"Diabetes mellitus is a metabolic disorder caused by genetic, environmental changes, mental health issues, immune disorders, and other factors. It may occur with or without insulin resistance, insulin secretion defect, or impaired biological function of insulin. The condition is characterized by chronic hyperglycemia and targeted damage to multiple systems and organs. Insulin pump therapy is an advanced method for managing diabetes that mimics the natural secretion of insulin by providing continuous delivery to diabetic patients. Compared to traditional multiple injections, the use of an insulin pump reduces the number of injections required and improves patient compliance and treatment convenience. The medical team can customize the insulin pump treatment based on each patient's specific situation in order to achieve optimal blood sugar control and effectively reduce the risk of complications. In recent years, there has been significant attention given to glucose-in-target time (TIR), which refers to the amount of time blood sugar levels are within a range of 3.9 to 10.0 mmol\u002FL in non-pregnant adults measured either as minutes or as a percentage (%). This clinical trial aims to collect data on using an insulin pump (Model: AR-B200A) combined with a scanning glucose monitoring system (Model: FreeStyle Libre, 20163072472) for continuous subcutaneous insulin infusion in type 1 diabetes patients in order to provide reference for related clinical applications.",[110,111,30],"Type 1 Diabetes Mellitus","Insulin Pump",[113,114,115],"type 1 diabetes","insulin pump","time in range","2024-12-15",{"date":118,"type":36},"2024-12-19",{"date":120,"type":21},"2024-12-11",{"date":122,"type":21},"2025-12",{"name":124,"class":43},"Tao Yuan，MD"]